Milk-Born Bioactive Peptide-EGF and Its Intestinal Protection--Chapter III

Views : 11
Author : Rota
Update time : 2023-04-28 09:27:31

EGF in Developing Gut

Epidermal growth factor (EGF) was first isolated from mouse salivary glands and recognized by its ability to accelerate the eruption of mouse teeth and the opening of eyelids of newborn mice . Human EGF was initially detected in urine  and then measured in many tissuesand body fluids . EGF is a heat- and acid-stable peptide that produces a variety of biologic responses, most of which involve regulation of cell replication, cell movement and cell survival . In the GI tract, EGF enhances proliferation and differentiation of epithelial cells, but also has significant effects on healing of damaged mucosa or on intestinal adaptation after injury. Fetal intestine is exposed to EGF in amniotic fluid. Amniotic fluid contains significant concentrations of EGF that gradually increase during pregnancy, with the highest level achieved at the end of the normal gestation period . In the postnatal period, the major sources of intestinal EGF are maternal colostrum and milk Human milk EGF levels are the highest in the first days after parturition (approximately 100 ng/mL) and then gradually decrease during the first month of lactation . Interestingly, EGF levels in milk of mothers with extremely pre-term neonates are 50-80% higher compared with those in milk of mothers with full-term infants . Although the physiologic relevance of this observation is still not fully understood, elevated levels of EGF in human milk may be responsible for the protective effect of maternal milk against neonatal intestinal diseases, such as necrotizing enterocolitis(NEC).


Referance and source:
J Pediatr. 2010 February ; 156(2 Suppl): S31–S35. doi:10.1016/j.jpeds.2009.11.018.

Related News
Read More >>
Ⅴ-Immune Regulation, Host Defense Guards are Varied Ⅴ-Immune Regulation, Host Defense Guards are Varied
Apr .24.2023
Multifunctional cationic host Defense Peptides and Their Clinical Application consists of 12 chapters. The selected sections of this article is Chapter 5 --Immune regulation, Host defense guards are varied
Ⅳ-Fighting Cancer Cells, Host Defense Guards Have Potential Ⅳ-Fighting Cancer Cells, Host Defense Guards Have Potential
Mar .31.2023
However, these peptides have no anticancer activity in vivo because the peptides are inactivated in serum. Interestingly, however, peptides composed of D-amino acids significantly inhibited the growth of human prostate and breast cancers in xenografts and in ACID/NCr mice, respectively.
Ⅲ-The clinical application of host defense proteins is in full swing Ⅲ-The clinical application of host defense proteins is in full swing
Mar .30.2023
There are twelve chapters in Multifunctional Cationic Host Defense Peptides and Their Clinical Applications This article is serialized as an excerpt: Chapter 3 The Body's Defense Guards - Host Defense Proteins
Ⅰ-The Body's Defense Guards - Host Defense Proteins Ⅰ-The Body's Defense Guards - Host Defense Proteins
Mar .30.2023
There are twelve chapters in Multifunctional Cationic Host Defense Peptides and Their Clinical Applications This article is serialized as an excerpt: Chapter 1 The Body's Defense Guards - Host Defense Proteins